Middle East and Africa Neurological Biomarker Market Trends and Analysis by 2027

The Middle East and Africa neurological biomarker market is expected to reach US$ 529.04 million by 2027 from US$ 232.80 million in 2019; it is estimated to grow at a CAGR of 11.0% from 2020 to 2027.

The growth of the market is attributed to a few key driving factors such as rising prevalence of neurological diseases and growing focus on neurological biomarker research. On the other hand, concerns associated with the use of biomarkers such as the absence of pre-analytical tests are among the major factors that hinder the market growth.

Neurological biomarkers are molecules present in the cerebral spinal fluid (CSF) or blood that support the diagnosis of brain disorders and monitor disease progression. These biomarkers' primary sources are genetic mutations, metabolite levels, brain imaging, and changes in protein expression or post-translational modifications. This helps in the early detection of disease and less invasive diagnostics. It also allows faster drug development and is expected to be the effective treatment for Neurological disorders. Currently, research activities focused on biomarkers in neurodegenerative diseases are significantly increasing due to the surging incidence of Alzheimer’s and Parkinson’s diseases across Middle East and Africa. The World Alzheimer's Report 2017 estimated that 4.4 million people aged 60 years and above were living in South Africa, from which ~ 187,000 had Alzheimer’s dementia. Also, the introduction of digital biomarkers and the growing focus on neurological biomarker research are anticipated to propel the growth of the Middle East and Africa neurological biomarker market in the coming years.

The COVID-19 outbreak pandemic has adversely affected the countries in the Middle East and Africa. Patients suffering from severe health conditions such as neurological diseases have been witnessing delays in chronic disease treatment. However, many companies and research institutes are taking initiatives to accelerate research in the diagnosis, treatment, and prevention of the neurological complications that may be caused by COVID-19. Thus, the Middle East and Africa neurological biomarker market is facing challenges due to the COVID-19 outbreak.

Middle East and Africa Neurological Biomarkers MarketSegmentation

By Product

• Proteomics Biomaker
• Genomics Biomarker
• Metabolomics Biomarker
• Imaging Biomarker
• Others

By Application

• Alzheimer's Disease
• Parkinson's Disease
• Schizophrenia
• Huntington's Disease
• Spinal Muscular Atrophy
• Others

By End User

• Pharmaceutical and Biotechnology Companies
• Clinical Diagnostics
• Research Organizations

By Country

• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East and Africa

Company Profiles

• Thermo Fisher Scientific Inc.
• Abbott
• Bio-Rad Laboratories Inc.
• QIAGEN
• Immunarray Pvt. Ltd.
• Quest Diagnostics Incorporated
• Perkin Elmer, Inc
• MERCK KGaA

Middle East and Africa Neurological Biomarker Report Scope